# Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

> **NCT04526197** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Wilson Disease

## Interventions

- **DRUG:** ALXN1840
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT04526197
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-07
- **Primary completion:** 2020-11-03
- **Final completion:** 2020-11-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526197, "Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04526197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*